ATTOAtento S.A.
20.80USDMkt Cap: —P/E: —3d ago
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
Key Statistics
Company
Market Cap—
Enterprise Value224.24M $
Revenue (TTM)1.35M $
Gross Profit-57.61M $
Net Income (TTM)-60.63M $
Revenue/Share0.3340 USD
Last Price20.80 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees44
CountryUS
SectorIndustrials
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.20
EV/Revenue166.10
P/S—
P/B-0.75
EPS (TTM)-2.50
EPS (Forward)—
52W Range
19.7084% of range21.01
52W High21.01 USD
52W Low19.70 USD
Profitability
Gross Margin0.00%
Oper. Margin-5260.00%
EBITDA Margin0.00%
Profit Margin-4490.89%
ROE56.43%
ROA-36.55%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-59.20M $
CapEx (TTM)2.31M $
FCF Margin—
FCF Yield—
Net Debt-127.82M $
Net Debt/EBITDA1.82
Balance Sheet
Debt/Equity-0.05
Current Ratio13.94
Quick Ratio13.61
Book Value/Sh-27.8240 USD
Cash/Share29.40 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.43.03M
Float2.48M
Insiders23.70%
Institutions47.62%
Technical
SMA 5020.55 (+1.2%)
SMA 20020.55 (+1.2%)
Beta—
S&P 52W Chg19.18%
Avg Vol (30d)361.56K
Avg Vol (10d)346.22K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—